← Back to Search

Diuretic

Bumetanide for Alzheimer's Disease (BumxAD Trial)

Phase 2

Recruiting

Led By Kyan Younes, MD

Research Sponsored by Stanford University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Mild cognitive impairment or mild dementia due to Alzheimer's disease

Alzheimer's disease medications are planned to remain stable throughout

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 6 months

Awards & highlights

BumxAD Trial Summary

This trial is studying if bumetanide, a diuretic, can be used to treat Alzheimer's disease. It will also assess its safety and the clinical and biomarker effects on those with mild cognitive impairment or mild dementia.

Who is the study for?

This trial is for adults with mild cognitive impairment or early-stage Alzheimer's disease who are stable on their current Alzheimer's medications. They must be able to complete tests and an MRI. People can't join if they have significant lab test abnormalities, chronic liver disease, kidney issues, uncontrolled high blood pressure, or take certain drugs like lithium.Check my eligibility

What is being tested?

The study is testing bumetanide—a diuretic approved for edema and hypertension—to see if it's safe and tolerable for Alzheimer's patients. It also looks at whether bumetanide affects symptoms or biomarkers of the disease compared to a placebo (a substance with no therapeutic effect).See study design

What are the potential side effects?

Bumetanide may cause dehydration due to increased urination, electrolyte imbalances (like low potassium), dizziness, potential hearing damage (ototoxicity), and could worsen kidney function in those already at risk.

BumxAD Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have mild memory loss or mild dementia because of Alzheimer's.

Select...

My Alzheimer's medications will not change during the study.

BumxAD Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 6 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~6 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Incidence of Treatment-Related Adverse Events

Secondary outcome measures

Change from baseline in The Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog13)

Changed from baseline in the clinical dementia rating scale sum of boxes (CDR-SoB)

BumxAD Trial Design

3Treatment groups

Active Control

Placebo Group

Group I: Bumetanide low doseActive Control1 Intervention

15 participants will take bumetanide low dose orally for 6 months and will be evaluated on cognitive and functional tests. Participants blood samples will be tested for levels of proteins involved in Alzheimer's disease.

Group II: Bumetanide high doseActive Control1 Intervention

15 participants will take bumetanide high dose orally for 6 months and will be evaluated on cognitive and functional tests. Participants blood samples will be tested for levels of proteins involved in Alzheimer's disease.

Group III: PlaceboPlacebo Group1 Intervention

10 participants will take placebo orally for 6 months and will be evaluated on cognitive and functional tests. Participants blood samples will be tested for levels of proteins involved in Alzheimer's disease.

0 / 2Eligibility criteria met

Find a Location

Who is running the clinical trial?

Stanford UniversityLead Sponsor

2,395 Previous Clinical Trials

17,341,310 Total Patients Enrolled

Kyan Younes, MDPrincipal InvestigatorStanford University

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is enrollment open to elderly individuals for this clinical study?

"Those who are between the age of 50 and 85 may be considered for participation in this clinical research."

Answered by AI

To what degree can Bumetanide low dose be considered hazardous for individuals?

"In terms of safety, Bumetanide low dose carries a rating of 2 since Phase 2 trials have produced evidence in support of its security but not efficacy."

Answered by AI

Could I qualify to join this experiment?

"This research study is recruiting 40 seniors with Alzheimer's disease between the ages of 50 and 85. Eligibility requirements include mild cognitive impairment or mild dementia due to Alzheimer’s, as well as a planned stability in medication intake throughout the course of the trial."

Answered by AI

Are researchers still recruiting participants for this experiment?

"Unfortunately, according to the information documented on clinicaltrials.gov, this medical study is not currently enrolling patients. The trial was first posted on October 15th 2023 and last updated two weeks later on September 18th of that same year; however, there are 544 other studies actively looking for volunteers at present."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Bumetanide in Patients With Alzheimer's Disease

Kyan Younes 2023. "Bumetanide in Patients With Alzheimer's Disease". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06052163.